Idexx Laboratories (IDXX) Liabilities and Shareholders Equity (2009 - 2026)

Idexx Laboratories' Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $3.4 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 5.35% year-over-year to $3.4 billion; the TTM figure through Mar 2026 stood at $13.5 billion (up 1.36% YoY), while the FY2025 annual figure was $3.4 billion, up 1.74% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $3.4 billion, up from $3.4 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $3.4 billion in Q2 2024, with the low at $2.6 billion in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $3.3 billion (2023), against an average of $3.1 billion.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity rose 19.41% in 2024, then dropped 4.17% in 2025.
• Idexx Laboratories' Liabilities and Shareholders Equity stood at $2.7 billion in 2022, then increased by 18.68% to $3.3 billion in 2023, then grew by 1.03% to $3.3 billion in 2024, then gained by 1.74% to $3.4 billion in 2025, then climbed by 1.04% to $3.4 billion in 2026.
• Business Quant data shows IDXX's Liabilities and Shareholders Equity at $3.4 billion in Q1 2026, $3.4 billion in Q4 2025, and $3.4 billion in Q3 2025.